欧州連合 -
ドイツ語 -
EMA (European Medicines Agency)
vocabria
viiv healthcare b.v. - cabotegavir sodium, cabotegravir - hiv-infektionen - antivirale mittel zur systemischen anwendung - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.
スイス -
ドイツ語 -
Swissmedic (Swiss Agency for Therapeutic Products)
vocabria 30 mg filmtabletten
viiv healthcare gmbh - cabotegravirum - filmtabletten - cabotegravirum 30 mg ut cabotegravirum natricum, lactosum monohydricum 163.59 mg, cellulosum microcristallinum, hypromellosum, carboxymethylamylum natricum a, magnesii stearas, Überzug: hypromellosum e 171, macrogolum 400, pro compresso obducto corresp. natrium 2.67 - 3.59 mg. - hiv-infektion - synthetika
スイス -
ドイツ語 -
Swissmedic (Swiss Agency for Therapeutic Products)
vocabria 400 mg / 2 ml depot-injektionssuspension
viiv healthcare gmbh - cabotegravirum - depot-injektionssuspension - cabotegravirum 400 mg, mannitolum, polysorbatum 20, macrogolum 3350, aqua ad iniectabile, ad solutionem pro 2 ml. - hiv-infektion - synthetika
スイス -
ドイツ語 -
Swissmedic (Swiss Agency for Therapeutic Products)
vocabria 600 mg / 3 ml depot-injektionssuspension
viiv healthcare gmbh - cabotegravirum - depot-injektionssuspension - cabotegravirum 600 mg, mannitolum, polysorbatum 20, macrogolum 3350, aqua ad iniectabile, ad solutionem pro 3 ml. - hiv-infektion - synthetika
欧州連合 -
ドイツ語 -
EMA (European Medicines Agency)
apretude
viiv healthcare b.v. - cabotegravir - hiv-infektionen - antivirale mittel zur systemischen anwendung - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4. 2, 4. 4 und 5.